Literature DB >> 9307553

Nonvalvular atrial fibrillation: evidence for a prothrombotic state.

S R Kahn1, S Solymoss, K M Flegel.   

Abstract

OBJECTIVE: To determine whether patients with nonvalvular atrial fibrillation (NVAF) have prothrombotic changes compared with patients in sinus rhythm.
DESIGN: Cross-sectional study. Hemostatic function compared in NVAF patients without prior embolic event (transient ischemic attack or embolic stroke) and control subjects without prior thrombotic stroke, and in NVAF patients with prior embolic event and control subjects with prior thrombotic stroke.
SETTING: Internal medicine outpatient group practice and anticoagulation clinic in 2 teaching hospitals. PATIENTS: A total of 75 NVAF patients (50 without and 25 with prior embolic event) and 42 control patients (31 without and 11 with prior thrombotic stroke) recruited concurrently over 18 months during 1990-91. OUTCOME MEASURES: Platelet count, prothrombin time (PT), partial thromboplastin time (PTT), and plasma levels of hemoglobin, fibrinogen, von Willebrand factor antigen, factor VIII, fibrin D-dimer, antithrombin III, protein C, protein S, fibrinopeptide A and prothrombin fragment F1+2. All statistical analyses were performed after adjustments for age and sex.
RESULTS: The NVAF patients without a prior embolic event had significantly higher mean hemoglobin and fibrinogen levels (p < 0.001 and p = 0.05, respectively) than the control subjects without prior thrombotic stroke. The 29 NVAF patients not taking warfarin (none had had an embolic event) had significantly lower mean protein C and protein S levels (p = 0.012 and p < 0.001, respectively) and a significantly higher fibrinopeptide A level (p = 0.03, after exclusion of outliers) than the control subjects without prior stroke. The NVAF patients with a prior embolic event had alterations in the hemostatic variables similar to those seen in the control patients with a prior thrombotic stroke. The latter had significantly higher fibrinogen, von Willebrand factor antigen and factor VIII levels (p = 0.04, 0.002 and 0.002, respectively) and significantly lower protein S levels (p = 0.02) than the control subjects without prior stroke.
CONCLUSIONS: NVAF patients without a history of an embolic event show evidence of a prothrombotic state compared with patients in sinus rhythm who have not had a thrombotic stroke. NVAF patients with a history of an embolic event show evidence of a prothrombotic state similar to that of patients in sinus rhythm who have had a thrombotic stroke. Prospective studies are needed to determine whether these abnormalities predict higher risk of stroke in individual NVAF patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307553      PMCID: PMC1228105     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  35 in total

1.  A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma.

Authors:  R M HARDISTY; J C MACPHERSON
Journal:  Thromb Diath Haemorrh       Date:  1962-05-15

2.  Hemostatic markers in acute transient ischemic attacks.

Authors:  E A Fon; A Mackey; R Côté; C Wolfson; D M McIlraith; J Leclerc; F Bourque
Journal:  Stroke       Date:  1994-02       Impact factor: 7.914

3.  Importance of the hematocrit as a risk factor in cerebral infarction.

Authors:  H Tohgi; H Yamanouchi; M Murakami; M Kameyama
Journal:  Stroke       Date:  1978 Jul-Aug       Impact factor: 7.914

4.  Plasma fibrinopeptide A levels in symptomatic venous thromboembolism.

Authors:  I M Yudelman; H L Nossel; K L Kaplan; J Hirsh
Journal:  Blood       Date:  1978-06       Impact factor: 22.113

5.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

6.  Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease.

Authors:  F G Fowkes; G D Lowe; E Housley; A Rattray; A Rumley; R A Elton; I R MacGregor; J Dawes
Journal:  Lancet       Date:  1993-07-10       Impact factor: 79.321

7.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.

Authors:  P A Wolf; T R Dawber; H E Thomas; W B Kannel
Journal:  Neurology       Date:  1978-10       Impact factor: 9.910

8.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  S G Thompson; J Kienast; S D Pyke; F Haverkate; J C van de Loo
Journal:  N Engl J Med       Date:  1995-03-09       Impact factor: 91.245

9.  Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.

Authors:  N Ono; T Koyama; A Suehiro; K Oku; K Fujikake; E Kakishita
Journal:  Int Angiol       Date:  1992 Oct-Dec       Impact factor: 2.789

10.  Effect of haematocrit on cerebral blood-flow in man.

Authors:  D J Thomas; J Marshall; R W Russell; G Wetherley-Mein; G H du Boulay; T C Pearson; L Symon; E Zilkha
Journal:  Lancet       Date:  1977-11-05       Impact factor: 79.321

View more
  16 in total

Review 1.  When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg?

Authors:  K M Flegel
Journal:  CMAJ       Date:  1999-04-20       Impact factor: 8.262

Review 2.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

3.  Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project.

Authors:  José Miguel Rivera-Caravaca; Vanessa Roldán; Marta Romera; María Asunción Esteve-Pastor; Mariano Valdés; Gregory Y H Lip; Vicente Vicente; Francisco Marín
Journal:  J Gen Intern Med       Date:  2018-03-22       Impact factor: 5.128

Review 4.  Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes.

Authors:  Laila Staerk; Jason A Sherer; Darae Ko; Emelia J Benjamin; Robert H Helm
Journal:  Circ Res       Date:  2017-04-28       Impact factor: 17.367

5.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

Review 6.  New approaches to anticoagulation in atrial fibrillation.

Authors:  Palle Petersen
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

Review 7.  Von Willebrand Factor Plasma Levels Variability In Nonvalvular Atrial Fibrillation.

Authors:  Gerardo Muñoz Cortés; Martha Eva Viveros Sandoval; Carlos Arturo Areán Martínez; Helios Eduardo Vega Gómez; Sandra Edith López Castañeda; Anel Gómez García
Journal:  J Atr Fibrillation       Date:  2014-12-31

8.  Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.

Authors:  Alan S Go; Margaret C Fang; Natalia Udaltsova; Yuchiao Chang; Niela K Pomernacki; Leila Borowsky; Daniel E Singer
Journal:  Circulation       Date:  2009-03-02       Impact factor: 29.690

9.  Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression.

Authors:  Na Wu; Shifei Tong; Ying Xiang; Long Wu; Bin Xu; Yao Zhang; Xiangyu Ma; Yafei Li; Zhiyuan Song; Li Zhong
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

10.  EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  J Arrhythm       Date:  2016-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.